{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:36:14Z","timestamp":1792506974959,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In Soli\u2010CGM, treatment with iGlarLixi (insulin glargine 100\u2009U\/mL and lixisenatide 33\u2009\u03bcg\/mL) in insulin\u2010naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%\u201313% on \u22652 oral antihyperglycaemic agents (OADs)\u2009\u00b1\u2009glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101 RA) therapy) increased time in range (TIR; primary endpoint) from 26.4% at baseline to 52.7% at Week 16. This exploratory analysis examined the impact of treatment with iGlarLixi on patient\u2010reported treatment satisfaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Soli\u2010CGM was a single\u2010arm, 16\u2010week, multicentre, interventional, open\u2010label, phase 4 study using blinded continuous glucose monitoring (CGM; FreeStyle Libre Pro) to assess glycaemic metrics (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009124). CGM data were collected for a 2\u2010week period before initiation of iGlarLixi, and after treatment with iGlarLixi (Weeks 14\u201316). Treatment satisfaction was assessed using the Diabetes Medication Treatment Satisfaction Tool (DM\u2010SAT, which comprises four domains: well\u2010being, medical control, lifestyle and convenience), at baseline and end\u2010of\u2010treatment. Association of TIR and overall satisfaction (sum of all items) was also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 118 (95.9%) and 107 (87.0%) participants completed the DM\u2010SAT at baseline and Week 16, respectively. Mean overall score increased by 0.18, from 0.59 (baseline) to 0.78 (Week 16). A trend in improvement in score was observed in all domains. Improvement in TIR had a positive, but weak, trend of association with improvement in overall treatment satisfaction (mean\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.14).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In people with T2D suboptimally controlled on \u22652 OADs\u2009\u00b1\u2009GLP\u20101 RA, 16\u2009weeks' treatment with iGlarLixi resulted in a trend of improvement in treatment satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16251","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T04:16:46Z","timestamp":1739506606000},"page":"2523-2530","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment satisfaction and time in range after 16\u2009weeks of treatment with\n                    <scp>iGlarLixi<\/scp>\n                    in insulin\u2010naive adults with suboptimally controlled type 2 diabetes"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-7107","authenticated-orcid":false,"given":"Viral N.","family":"Shah","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Dex","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Meneghini","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Ividata  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Polonsky","sequence":"additional","affiliation":[{"name":"Behavioral Diabetes Institute  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2011"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164116679775"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00905-y"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14154"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.02.001"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd19-0093"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-0870-x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1600"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1581"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0310"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16214"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S24752"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.05.001"},{"key":"e_1_2_9_17_1","first-page":"923","article-title":"Real\u2010world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi\u2010injective insulin therapy","volume":"25","author":"Persano M","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14822"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0856"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7327"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds20-0096"},{"key":"e_1_2_9_22_1","unstructured":"Centers for Medicare and Medicaid Services.Diabetes disparities in Medicare fee\u2010for\u2010service enrollees.2024.https:\/\/www.cms.gov\/About\u2010CMS\/Agency\u2010Information\/OMH\/Downloads\/Data\u2010Snapshots\u2010Diabetes.pdf. Accessed 13 August 2024."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-015-1302-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06052-w"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2623"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0393"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112341"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:55:01Z","timestamp":1761864901000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/dom.16251"],"URL":"https:\/\/doi.org\/10.1111\/dom.16251","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16251\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16251\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16251\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16251\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16251\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"2024-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}